Conditions: Chronic Hepatitis C Virus (HCV) Infection
Keywords: Treatment-Naive Hepatitis C Virus Genotype 2 Sofosbuvir (SOF)-Experienced Treatment-Experienced Non-cirrhotic
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 304
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the safety and efficacy of ABT-493/ABT-530 in adults with genotype 2 chronic hepatitis C virus (HCV) infection.

Detailed description:

Arms:
arm 1: ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks (double-blind \[DB\] treatment period) arm 2: Placebo for ABT-493/ABT-530 QD for 12 weeks (DB treatment period) arm 3: ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks (open-label \[OL\] treatment period)

Interventions: intervention 1: ABT-493/ABT-530 intervention 2: Placebo for ABT-493/ABT-530
Intervention descriptions: intervention 1: Tablet; ABT-493 coformulated with ABT-530 intervention 2: tablet

Protocol document: